The primary objective of this study is to evaluate the association between hemoglobin levels in the cerebrospinal fluid (CSF-Hb) and the occurrence of secondary brain injury in patients after aneurysmal subarachnoid hemorrhage (SAH-SBI) during the first 14 days after bleeding.
This is an international multicentre observational study to validate cerebrospinal fluid hemoglobin (CSF-Hb) as a monitoring biomarker for aneurysmal subarachnoid hemorrhage related secondary brain injury (SAH-SBI). It is hypothesized that there is an association between the concentration of CSF-Hb and the occurrence of SAH-SBI during the first 14 days after the bleeding (post-SAH). The primary objective of this study is to evaluate the association between ventricular CSF-Hb and SAH-SBI during the first 14 days post-SAH. The secondary objectives are to investigate: * the association between ventricular CSF-Hb and angiographic vasospasms (aVSP), delayed cerebral ischemia (DCI) and delayed ischemic neurological deficits (DIND) during the first 14 days post-SAH, * the accuracy of ventricular CSF-Hb to monitor for aVSP, DCI and DIND during the first 14 days post-SAH, * the association between lumbar CSF-Hb and SAH-SBI, aVSP, DCI and DIND during the first 14 days post-SAH, * the accuracy of lumbar CSF-Hb to monitor for aVSP, DCI and DIND during the first 14 days post-SAH, * the association between baseline measures and CSF-Hb (ventricular and lumbar during the first 14 days post-SAH), * the association between CSF-Hb (ventricular and lumbar during the first 14 days post-SAH) and co-interventions/complications, * the association between CSF-Hb (ventricular and lumbar during the first 14 days post-SAH) and chronic hydrocephalus at 12 weeks follow-up, * the association between CSF-Hb (ventricular and lumbar during the first 14 days post-SAH) and functional outcome at 12 weeks follow-up, * exploratory CSF proteome/metabolome analyses to assess Hb toxicity, inflammation, neuronal, or vascular damage.
Study Type
OBSERVATIONAL
Enrollment
366
Johannes Kepler Universität Linz, Universitätsklinik für Neurochirurgie
Linz, Austria
Medizinische Universität Wien, Klinik für Neurochirurgie
Vienna, Austria
Universitätsklinikum Mannheim
Mannheim, Baden-Wurttemberg, Germany
Klinikum rechts der Isar TUM
Aneurysmal subarachnoid hemorrhage related secondary brain injury (SAH-SBI)
Composite outcome consisting of angiographic vasospasms (aVSP), delayed cerebral ischemia (DCI), or delayed ischemic neurological deficits (DIND).
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Angiographic vasospasms (aVSP)
The definition of aVSP comprises a narrowing of cerebral arteries based on a digital subtraction angiography (DSA), CT angiography (CTA) or magnetic resonance angiography (MRA). In the absence of an appropriate imaging procedure on the respective day, this will be noted as no imaging performed.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Delayed cerebral ischemia (DCI)
DCI is defined as new ischemia or new infarction on CT/perfusion CT or MRI. In the absence of an appropriate imaging procedure on the respective day, this will be noted as no imaging performed.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Delayed ischemic neurologic deficits (DIND)
DIND is defined as a new focal neurological deficit or a decrease in Glasgow Coma Scale (GCS) of at least 2 points for at least 2 hours. In case the patient cannot be clinically assessed (e.g., sedation), this will be noted as non-assessable).
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Co-intervention 1: Nimodipine treatment
Whether the patient received preventive nimodipine treatment within the past 24 hours.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Co-intervention 2: Spasmolysis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
München, Bavaria, Germany
Universitätsklinikum Tübingen
Tübingen, Tübingen, Germany
Kantonsspital Aarau
Aarau, Canton of Aargau, Switzerland
Kantonsspital St. Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland
University Hospital Zurich
Zurich, Canton of Zurich, Switzerland
Whether a rescue therapy with pharmacological spasmolysis or balloon angioplasty was performed within the past 24 hours.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Co-intervention 3: Intraventricular administration of rtPA (ICV-rtPA)
Whether rtPA was administered via the EVD to induce blood clot lysis within the past 24 hours.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Co-intervention 4: Triple-H-therapy
A triple-H-therapy or elements of it (hypertension, hypervolemia or hemodilution) was induced within the past 24 hours.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Co-intervention 5: Decompression
A surgical decompression (e.g. decompressive hemicraniectomy) was performed within the past 24 hours.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Complication 1: CSF infection
Differentiated between infection (Clinical symptoms and signs of CSF infection and positive CSF culture), colonization (2 positive CSF cultures without clinical symptoms and signs) and contamination (1 positive CSF culture with consecutive culture being negative).
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Complication 2: Surgical site infection
Evidence for a surgical site infection at the EVD/LD skin entrance site.
Time frame: Day 1 to day 14 after the aneurysmal subarachnoid hemorrhage
Chronic hydrocephalus
Time frame: 12 weeks follow-up visit
Functional status 1: Glasgow Outcome Scale Extended [1-8]
1. Death 2. Vegetative state (unresponsive and speechless) 3. Lower severe disability (requires frequent help of someone to be around at home most of the time every day) 4. Upper severe diasbility (can be left alone \> 8h during the day, but unable to travel and/or go shopping without assistance) 5. Lower moderate disability (unable to work or only in sheltered workshop) 6. Upper moderate disability (reduced work capacity; resumes \<50% of the pre-injury level of social and leisure activities) 7. Lower good recovery (minor problems that affect daily life; resumes \>50% of the pre-injury level of social and leisure activities) 8. Upper good recovery (no current problems related to the brain injury that affect daily life)
Time frame: 12 weeks follow-up visit
Functional status 2: modified Rankin Scale [0-6]
0 No symptoms 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3. Moderate disability. Requires some helpt, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. Dead
Time frame: 12 weeks follow-up visit